First Author: S.C.Lee SOUTH KOREA
Co Author(s): H.S. Kim C.S. Lee J.H. Lee H.M. Kang 0 0 0 0 0 0 0 0 0
Back to previous
To investigate incidence, cause, and surgical outcome of pars plana vitrectomy (PPV) for vitreoretinal complications after ruthenium-106 (Ru-106) brachytherapy for Korean patients with choroidal melanoma.
Retrospective, consecutive study
The medical records of 54 patients who underwent Ru-106 brachytherapy and completed at least 1 year of follow-up were retrospectively reviewed. Collected data included best-corrected visual acuity (BCVA), tumor characteristics, and vitrectomy-related data such as interval between brachytherapy and surgery. Baseline characteristics and BCVA were compared between those who underwent vitrectomy [V(+) group] and those who did not [V(-) group].
During a mean follow-up of 36.5±18.6 months after brachytherapy, 16 patients (29.6%) underwent PPV due to exudative retinal detachment (10 eyes; 62.5%), vitreous hemorrhage (4 eyes; 25.0%), and vitreous opacity with pigment dispersion (2 eyes; 12.5%). Three patients needed enucleation afterwards due to tumor recurrence (1 patient) and painful eyes due to neovascular glaucoma (2 patients). Although there was no significant difference in baseline characteristics, the V(+) group showed significantly worse visual outcome than the V(-) group (P = 0.004).
Despite a successful anatomical outcome, patients who underwent PPV for vitreoretinal complications after Ru-106 brachytherapy for choroidal melanoma showed significantly worse visual outcome than those who did not receive this procedure.